• Please log in or register to access this feature.
You have full text access to this OnlineOpen article

Assessing analgesic actions of opioids by experimental pain models in healthy volunteers – an updated review

  1. Camilla Staahl1,2,*,
  2. Anne Estrup Olesen1,2,
  3. Trine Andresen1,2,
  4. Lars Arendt-Nielsen1,
  5. Asbjørn Mohr Drewes1,2

Article first published online: 15 MAY 2009

DOI: 10.1111/j.1365-2125.2009.03456.x

Issue

British Journal of Clinical Pharmacology

British Journal of Clinical Pharmacology

Volume 68, Issue 2, pages 149–168, August 2009

Additional Information

How to Cite

Staahl, C., Olesen, A. E., Andresen, T., Arendt-Nielsen, L. and Drewes, A. M. (2009), Assessing analgesic actions of opioids by experimental pain models in healthy volunteers – an updated review. British Journal of Clinical Pharmacology, 68: 149–168. doi: 10.1111/j.1365-2125.2009.03456.x

Author Information

  1. 1

    Center for Sensory-Motor Interactions (SMI), Department of Health Science and Technology, Aalborg University and

  2. 2

    Center for Visceral Biomechanics and Pain, Department of Gastroenterology, Aalborg Hospital, Århus University Hospital, Denmark

*Mrs Camilla Staahl MSc. (Pharm), PhD, Center for Sensory-Motor Interactions (SMI), Department of Health Science and Technology, Aalborg University, Fredrik Bajers Vej 7, 9000 Aalborg, Denmark Tel.: +45 51 25 12 11 E-mail: cst@smi.auc.dk

Publication History

  1. Issue published online: 7 AUG 2009
  2. Article first published online: 15 MAY 2009
  3. Received 2 October 2008Accepted 27 April 2009

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (1378K)

REFERENCES

  • 1
    Konig HH, Bernert S, Angermeyer MC. Health Status of the German Population: results of a Representative Survey Using the euroqol questionnaire. Gesundheitswesen 2005; 67: 173–82.
  • 2
    Drewes AM, Gregersen H, Arendt-Nielsen L. Experimental pain in gastroenterology: a reappraisal of human studies. Scand J Gastroenterol 2003; 38: 1115–30.
  • 3
    Arendt-Nielsen L, Curatolo M, Drewes A. Human experimental pain models in drug development: translational pain research. Curr Opin Investig Drugs 2007; 8: 41–53.
  • 4
    Graven-Nielsen T, Mense S. The peripheral apparatus of muscle pain: evidence from animal and human studies. Clin J Pain 2001; 17: 2–10.
  • 5
    Staahl C, Christrup LL, Andersen SD, Arendt-Nielsen L, Drewes AM. A comparative study of oxycodone and morphine in a multi-modal, tissue-differentiated experimental pain model. Pain 2006; 123: 28–36.
  • 6
    Staahl C, Olesen AE, Andresen T, Arendt-Nielsen L, Drewes AM. Assessing analgesic actions of non-opioid analgesics by experimental pain models in healthy volunteers – an updated review. Br J Clin Pharmacol 2009; (in press).
  • 7
    Staahl C, Reddy H, Andersen SD, Arendt-Nielsen L, Drewes AM. Multi-modal and tissue-differentiated experimental pain assessment: reproducibility of a new concept for assessment of analgesics. Basic Clin Pharmacol Toxicol 2006; 98: 201–11.
  • 8
    Luginbuhl M, Schnider TW, Petersen-Felix S, Arendt-Nielsen L, Zbinden AM. Comparison of five experimental pain tests to measure analgesic effects of alfentanil. Anesthesiology 2001; 95: 22–9.
  • 9
    Graven-Nielsen T, Mense S, Arendt-Nielsen L. Painful and non-painful pressure sensations from human skeletal muscle. Exp Brain Res 2004; 159: 273–83.
  • 10
    Handwerker HO, Kobal G. Psychophysiology of experimentally induced pain. Physiol Rev 1993; 73: 639–71.
  • 11
    Staahl C, Drewes AM. Experimental human pain models: a review of standardised methods for preclinical testing of analgesics. Basic Clin Pharmacol Toxicol 2004; 95: 97–111.
  • 12
    Gracely RH. Pain measurement. Acta Anaesthesiol Scand 1999; 43: 897–908.
  • 13
    Besson JM. The neurobiology of pain. Lancet 1999; 353: 1610–5.
  • 14
    Woolf CJ, Max MB. Mechanism-based pain diagnosis: issues for analgesic drug development. Anesthesiology 2001; 95: 241–9.
  • 15
    Dirks J, Petersen KL, Rowbotham MC, Dahl JB. Gabapentin suppresses cutaneous hyperalgesia following heat-capsaicin sensitization. Anesthesiology 2002; 97: 102–7.
  • 16
    Wallace MS, Barger D, Schulteis G. The effect of chronic oral desipramine on capsaicin-induced allodynia and hyperalgesia: a double-blinded, placebo-controlled, crossover study. Anesth Analg 2002; 95: 973–8, table.
  • 17
    Negus SS, Vanderah TW, Brandt MR, Bilsky EJ, Becerra L, Borsook D. Preclinical assessment of candidate analgesic drugs: recent advances and future challenges. J Pharmacol Exp.Ther 2006; 319: 507–14.
  • 18
    Hughes AM, Rhodes J, Fisher G, Sellers M, Growcott JW. Assessment of the effect of dextromethorphan and ketamine on the acute nociceptive threshold and wind-up of the second pain response in healthy male volunteers. Br J Clin Pharmacol 2002; 53: 604–12.
  • 19
    Arendt-Nielsen L, Chen AC. Lasers and other thermal stimulators for activation of skin nociceptors in humans. Neurophysiol Clin 2003; 33: 259–68.
  • 20
    Harrison JL, Davis KD. Cold-evoked pain varies with skin type and cooling rate: a psychophysical study in humans. Pain 1999; 83: 123–35.
  • 21
    Davis KD. Cold-induced pain and prickle in the glabrous and hairy skin. Pain 1998; 75: 47–57.
  • 22
    Narhi M, Jyvasjarvi E, Virtanen A, Huopaniemi T, Ngassapa D, Hirvonen T. Role of intradental A- and C-type nerve fibres in dental pain mechanisms. Proc Finn Dent Soc 1992; 88 (Suppl. 1): 507–16.
  • 23
    Chaves TC, Nagamine HM, De Sousa LM, De Oliveira AS, Grossi DB. Intra- and interrater agreement of pressure pain threshold for masticatory structures in children reporting orofacial pain related to temporomandibular disorders and symptom-free children. J Orofac Pain 2007; 21: 133–42.
  • 24
    Pasini FL, Capecchi PL, Colafati M, Randisi P, Puccetti L, Di PT. Systemic adenosine increase during cold pressor test is dependent on sympathetic activation. Clin Exp Pharmacol Physiol 1999; 26: 774–8.
  • 25
    Fagius J, Karhuvaara S, Sundlof G. The cold pressor test: effects on sympathetic nerve activity in human muscle and skin nerve fascicles. Acta Physiol Scand 1989; 137: 325–34.
  • 26
    Arendt-Nielsen L, Graven-Nielsen T, Svensson P, Jensen TS. Temporal summation in muscles and referred pain areas: an experimental human study. Muscle Nerve 1997; 20: 1311–3.
  • 27
    Arendt-Nielsen L, Petersen-Felix S, Fischer M, Bak P, Bjerring P, Zbinden AM. The effect of N-methyl-D-aspartate antagonist (ketamine) on single and repeated nociceptive stimuli: a placebo-controlled experimental human study. Anesth Analg 1995; 81: 63–8.
  • 28
    Cervero F, Laird JM, Garcia-Nicas E. Secondary hyperalgesia and presynaptic inhibition: an update. Eur J Pain 2003; 7: 345–51.
  • 29
    Pedersen JL. Inflammatory pain in experimental burns in man. Dan Med Bull 2000; 47: 168–95.
  • 30
    LaMotte RH, Lundberg LE, Torebjork HE. Pain, hyperalgesia and activity in nociceptive C units in humans after intradermal injection of capsaicin. J Physiol 1992; 448: 749–64.
  • 31
    Lotsch J, Angst MS. The mu-opioid agonist remifentanil attenuates hyperalgesia evoked by blunt and punctuated stimuli with different potency: a pharmacological evaluation of the freeze lesion in humans. Pain 2003; 102: 151–61.
  • 32
    Koppert W, Dern SK, Sittl R, Albrecht S, Schuttler J, Schmelz M. A new model of electrically evoked pain and hyperalgesia in human skin: the effects of intravenous alfentanil, S(+)-ketamine, and lidocaine. Anesthesiology 2001; 95: 395–402.
  • 33
    Koppert W, Sittl R, Scheuber K, Alsheimer M, Schmelz M, Schuttler J. Differential modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by S-ketamine and clonidine in humans. Anesthesiology 2003; 99: 152–9.
  • 34
    Segerdahl M. Multiple dose gabapentin attenuates cutaneous pain and central sensitisation but not muscle pain in healthy volunteers. Pain 2006; 125: 158–64.
  • 35
    Slater H, Arendt-Nielsen L, Wright A, Graven-Nielsen T. Experimental deep tissue pain in wrist extensors – a model of lateral epicondylalgia. Eur J Pain 2003; 7: 277–88.
  • 36
    Sarkar S, Aziz Q, Woolf CJ, Hobson AR, Thompson DG. Contribution of central sensitisation to the development of non-cardiac chest pain. Lancet 2000; 356: 1154–9.
  • 37
    Brennum J, Arendt-Nielsen L, Horn A, Secher NH, Jensen TS. Quantitative sensory examination during epidural anaesthesia and analgesia in man: effects of morphine. Pain 1993; 52: 75–83.
  • 38
    Bromm B, Treede RD. Laser-evoked cerebral potentials in the assessment of cutaneous pain sensitivity in normal subjects and patients. Rev Neurol (Paris) 1991; 147: 625–43.
  • 39
    Apkarian AV, Bushnell MC, Treede RD, Zubieta JK. Human brain mechanisms of pain perception and regulation in health and disease. Eur J Pain 2005; 9: 463–84.
  • 40
    Andersen OK, Felsby S, Nicolaisen L, Bjerring P, Jensen TS, Rendt-Nielsen L. The effect of ketamine on stimulation of primary and secondary hyperalgesic areas induced by capsaicin – a double-blind, placebo-controlled, human experimental study. Pain 1996; 66: 51–62.
  • 41
    Warncke T, Stubhaug A, Jorum E. Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain 1997; 72: 99–106.
  • 42
    Koppert W, Likar R, Geisslinger G, Zeck S, Schmelz M, Sittl R. Peripheral antihyperalgesic effect of morphine to heat, but not mechanical, stimulation in healthy volunteers after ultraviolet-B irradiation. Anesth Analg 1999; 88: 117–22.
  • 43
    Poyhia R, Vainio A. Topically administered ketamine reduces capsaicin-evoked mechanical hyperalgesia. Clin J Pain 2006; 22: 32–6.
  • 44
    Angst MS, Ramaswamy B, Davies MF, Maze M. Comparative analgesic and mental effects of increasing plasma concentrations of dexmedetomidine and alfentanil in humans. Anesthesiology 2004; 101: 744–52.
  • 45
    Olofsen E, Romberg R, Bijl H, Mooren R, Engbers F, Kest B, Dahan A. Alfentanil and placebo analgesia: no sex differences detected in models of experimental pain. Anesthesiology 2005; 103: 130–9.
  • 46
    Petersen-Felix S, Arendt-Nielsen L, Bak P, Bjerring P, Breivik H, Svensson P, Zbinden AM. Ondansetron does not inhibit the analgesic effect of alfentanil. Br J Anaesth 1994; 73: 326–30.
  • 47
    Petersen-Felix S, Arendt-Nielsen L, Bak P, Fischer M, Zbinden AM. Psychophysical and electrophysiological responses to experimental pain may be influenced by sedation: comparison of the effects of a hypnotic (propofol) and an analgesic (alfentanil). Br J Anaesth 1996; 77: 165–71.
  • 48
    Schulte H, Segerdahl M, Graven-Nielsen T, Grass S. Reduction of human experimental muscle pain by alfentanil and morphine. Eur J Pain 2006; 10: 733–41.
  • 49
    Wallace MS, Ridgeway B III, Leung A, Schulteis G, Yaksh TL. Concentration-effect relationships for intravenous alfentanil and ketamine infusions in human volunteers: effects on acute thresholds and capsaicin-evoked hyperpathia. J Clin Pharmacol 2002; 42: 70–80.
  • 50
    Oertel BG, Preibisch C, Wallenhorst T, Hummel T, Geisslinger G, Lanfermann H, Lotsch J. Differential opioid action on sensory and affective cerebral pain processing. Clin Pharmacol Ther 2008; 83: 577–88.
  • 51
    Chapman CR, Hill HF, Saeger L, Gavrin J. Profiles of opioid analgesia in humans after intravenous bolus administration: alfentanil, fentanyl and morphine compared on experimental pain. Pain 1990; 43: 47–55.
  • 52
    Black ML, Hill JL, Zacny JP. Behavioral and physiological effects of remifentanil and alfentanil in healthy volunteers. Anesthesiology 1999; 90: 718–26.
  • 53
    Schulte H, Graven-Nielsen T, Sollevi A, Jansson Y, Arendt-Nielsen L, Segerdahl M. Pharmacological modulation of experimental phasic and tonic muscle pain by morphine, alfentanil and ketamine in healthy volunteers. Acta Anaesthesiol Scand 2003; 47: 1020–30.
  • 54
    Eisenach JC, Hood DD, Curry R, Tong C. Alfentanil, but not amitriptyline, reduces pain, hyperalgesia, and allodynia from intradermal injection of capsaicin in humans. Anesthesiology 1997; 86: 1279–87.
  • 55
    Sethna NF, Liu M, Gracely R, Bennett GJ, Max MB. Analgesic and cognitive effects of intravenous ketamine-alfentanil combinations versus either drug alone after intradermal capsaicin in normal subjects. Anesth Analg 1998; 86: 1250–6.
  • 56
    Wallace MS, Braun J, Schulteis G. Postdelivery of alfentanil and ketamine has no effect on intradermal capsaicin-induced pain and hyperalgesia. Clin J Pain 2002; 18: 373–9.
  • 57
    Schulte H, Sollevi A, Segerdahl M. Dose-dependent effects of morphine on experimentally induced cutaneous pain in healthy volunteers. Pain 2005; 116: 366–74.
  • 58
    Koltzenburg M, Pokorny R, Gasser UE, Richarz U. Differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006; 126: 165–74.
  • 59
    Tucker AP, Kim YI, Nadeson R, Goodchild CS. Investigation of the potentiation of the analgesic effects of fentanyl by ketamine in humans: a double-blinded, randomised, placebo controlled, crossover study of experimental pain [ISRCTN83088383. BMC Anesthesiol 2005; 5: 2.
  • 60
    Ginosar Y, Riley ET, Angst MS. The site of action of epidural fentanyl in humans: the difference between infusion and bolus administration. Anesth Analg 2003; 97: 1428–38.
  • 61
    Hill HF, Chapman CR, Saeger LS, Bjurstrom R, Walter MH, Schoene RB, Kippes M. Steady-state infusions of opioids in human. II. Concentration-effect relationships and therapeutic margins. Pain 1990; 43: 69–79.
  • 62
    Price DD, Staud R, Robinson ME, Mauderli AP, Cannon R, Vierck CJ. Enhanced temporal summation of second pain and its central modulation in fibromyalgia patients. Pain 2002; 99: 49–59.
  • 63
    Curatolo M, Petersen-Felix S, Gerber A, Rendt-Nielsen L. Remifentanil inhibits muscular more than cutaneous pain in humans. Br J Anaesth 2000; 85: 529–32.
  • 64
    Gustorff B, Felleiter P, Nahlik G, Brannath W, Hoerauf KH, Spacek A, Kress HG. The effect of remifentanil on the heat pain threshold in volunteers. Anesth Analg 2001; 92: 369–74.
  • 65
    Luginbuhl M, Gerber A, Schnider TW, Petersen-Felix S, Rendt-Nielsen L, Curatolo M. Modulation of remifentanil-induced analgesia, hyperalgesia, and tolerance by small-dose ketamine in humans. Anesth Analg 2003; 96: 726–32.
  • 66
    Petersen KL, Jones B, Segredo V, Dahl JB, Rowbotham MC. Effect of remifentanil on pain and secondary hyperalgesia associated with the heat – capsaicin sensitization model in healthy volunteers. Anesthesiology 2001; 94: 15–20.
  • 67
    Petersen KL, Maloney A, Hoke F, Dahl JB, Rowbotham MC. A randomized study of the effect of oral lamotrigine and hydromorphone on pain and hyperalgesia following heat/capsaicin sensitization. J Pain 2003; 4: 400–6.
  • 68
    Wagner KJ, Sprenger T, Kochs EF, Tolle TR, Valet M, Willoch F. Imaging human cerebral pain modulation by dose-dependent opioid analgesia: a positron emission tomography activation study using remifentanil. Anesthesiology 2007; 106: 548–56.
  • 69
    Lorenz IH, Kolbitsch C, Hinteregger M, Bauer P, Spiegel M, Luger TJ, Schmidauer C, Streif W, Pfeiffer KP, Benzer A. Remifentanil and nitrous oxide reduce changes in cerebral blood flow velocity in the middle cerebral artery caused by pain. Br J Anaesth 2003; 90: 296–9.
  • 70
    Koppert W, Angst M, Alsheimer M, Sittl R, Albrecht S, Schuttler J, Schmelz M. Naloxone provokes similar pain facilitation as observed after short-term infusion of remifentanil in humans. Pain 2003; 106: 91–9.
  • 71
    Singler B, Troster A, Manering N, Schuttler J, Koppert W. Modulation of remifentanil-induced postinfusion hyperalgesia by propofol. Anesth Analg 2007; 104: 1397–403, table.
  • 72
    Troster A, Sittl R, Singler B, Schmelz M, Schuttler J, Koppert W. Modulation of remifentanil-induced analgesia and postinfusion hyperalgesia by parecoxib in humans. Anesthesiology 2006; 105: 1016–23.
  • 73
    Hood DD, Curry R, Eisenach JC. Intravenous remifentanil produces withdrawal hyperalgesia in volunteers with capsaicin-induced hyperalgesia. Anesth Analg 2003; 97: 810–5.
  • 74
    Tian YL, Guo Y, Cao DY, Zhang Q, Wang HS, Zhao Y. Local application of morphine suppresses glutamate-evoked activities of C and Adelta afferent fibers in rat hairy skin. Brain Res 2005; 1059: 28–34.
  • 75
    Hallin RG, Torebjork HE, Wiesenfeld Z. Nociceptors and warm receptors innervated by C fibres in human skin. J Neurol Neurosurg Psychiatry 1982; 45: 313–9.
  • 76
    Le Bars D, Gozariu M, Cadden SW. Animal models of nociception. Pharmacol Rev 2001; 53: 597–652.
  • 77
    Willer JC, Le Bars D, De Broucker T. Diffuse noxious inhibitory controls in man: involvement of an opioidergic link. Eur J Pharmacol 1990; 182: 347–55.
  • 78
    Dickenson AH. Spinal cord pharmacology of pain. Br J Anaesth 1995; 75: 193–200.
  • 79
    Cohen SP, Christo PJ, Wang S, Chen L, Stojanovic MP, Shields CH, Brummett C, Mao J. The effect of opioid dose and treatment duration on the perception of a painful standardized clinical stimulus. Reg Anesth Pain Med 2008; 33: 199–206.
  • 80
    Joly V, Richebe P, Guignard B, Fletcher D, Maurette P, Sessler DI, Chauvin M. Remifentanil-induced postoperative hyperalgesia and its prevention with small-dose ketamine. Anesthesiology 2005; 103: 147–55.
  • 81
    Naef M, Curatolo M, Petersen-Felix S, Arendt-Nielsen L, Zbinden A, Brenneisen R. The analgesic effect of oral delta-9-tetrahydrocannabinol (THC), morphine, and a THC-morphine combination in healthy subjects under experimental pain conditions. Pain 2003; 105: 79–88.
  • 82
    Le Bars D, Guilbaud G, Jurna I, Besson JM. Differential effects of morphine on responses of dorsal horn lamina V type cells elicited by A and C fibre stimulation in the spinal cat. Brain Res 1976; 115: 518–24.
  • 83
    Van Der Burght M, Rasmussen SE, Arendt-Nielsen L, Bjerring P. Morphine does not affect laser induced warmth and pin prick pain thresholds. Acta Anaesthesiol Scand 1994; 38: 161–4.
  • 84
    Arendt-Nielsen L, Bjerring P, Dahl JB. A quantitative double-blind evaluation of the antinociceptive effects of perineurally administered morphine compared with lidocaine. Acta Anaesthesiol Scand 1991; 35: 24–9.
  • 85
    Arendt-Nielsen L, Oberg B, Bjerring P. Hypoalgesia following epidural morphine: a controlled quantitative experimental study. Acta Anaesthesiol Scand 1991; 35: 430–5.
  • 86
    Quante M, Scharein E, Zimmermann R, Langer-Brauburger B, Bromm B. Dissociation of morphine analgesia and sedation evaluated by EEG measures in healthy volunteers. Arzneimittelforschung 2004; 54: 143–51.
  • 87
    Eckhardt K, Ammon S, Hofmann U, Riebe A, Gugeler N, Mikus G. Gabapentin enhances the analgesic effect of morphine in healthy volunteers. Anesth Analg 2000; 91: 185–91.
  • 88
    Grach M, Massalha W, Pud D, Adler R, Eisenberg E. Can co-administration of oxycodone and morphine produce analgesic synergy in humans? An experimental cold pain study. Br J Clin Pharmacol 2004; 58: 235–42.
  • 89
    Plesan A, Sollevi A, Segerdahl M. The N-methyl-D-aspartate-receptor antagonist dextromethorphan lacks analgesic effect in a human experimental ischemic pain model. Acta Anaesthesiol Scand 2000; 44: 924–8.
  • 90
    Pud D, Yarnitsky D, Sprecher E, Rogowski Z, Adler R, Eisenberg E. Can personality traits and gender predict the response to morphine? An experimental cold pain study. Eur J Pain 2006; 10: 103–12.
  • 91
    Segerdahl M, Ekblom A, Sollevi A. The influence of adenosine, ketamine, and morphine on experimentally induced ischemic pain in healthy volunteers. Anesth Analg 1994; 79: 787–91.
  • 92
    Smith GM, Egbert LD, Markowitz RA, Mosteller F, Beecher HK. An experimental pain method sensitive to morphine in man: the submaximum effort tourniquet technique. J Pharmacol Exp Ther 1966; 154: 324–32.
  • 93
    Moiniche S, Dahl JB, Kehlet H. Peripheral antinociceptive effects of morphine after burn injury. Acta Anaesthesiol Scand 1993; 37: 710–2.
  • 94
    Schulte H, Sollevi A, Segerdahl M. The synergistic effect of combined treatment with systemic ketamine and morphine on experimentally induced windup-like pain in humans. Anesth Analg 2004; 98: 1574–80.
  • 95
    Tegeder I, Meier S, Burian M, Schmidt H, Geisslinger G, Lotsch J. Peripheral opioid analgesia in experimental human pain models. Brain 2003; 126: 1092–102.
  • 96
    Roberts JD, Gennings C, Shih M. Synergistic affective analgesic interaction between delta-9-tetrahydrocannabinol and morphine. Eur J Pharmacol 2006; 530: 54–8.
  • 97
    Price DD, Von der GA, Miller J, Rafii A, Price C. A psychophysical analysis of morphine analgesia. Pain 1985; 22: 261–9.
  • 98
    D’Honneur G, Gilton A, Sandouk P, Scherrmann JM, Duvaldestin P. Plasma and cerebrospinal fluid concentrations of morphine and morphine glucuronides after oral morphine. The influence of renal failure. Anesthesiology 1994; 81: 87–93.
  • 99
    Lotsch J. Pharmacokinetic-pharmacodynamic modeling of opioids. J Pain Symptom Manage 2005; 29: S90–103.
  • 100
    Enggaard TP, Poulsen L, Arendt-Nielsen L, Hansen SH, Bjornsdottir I, Gram LF, Sindrup SH. The analgesic effect of codeine as compared to imipramine in different human experimental pain models. Pain 2001; 92: 277–82.
  • 101
    Poulsen L, Rendt-Nielsen L, Brosen K, Nielsen KK, Gram LF, Sindrup SH. The hypoalgesic effect of imipramine in different human experimental pain models. Pain 1995; 60: 287–93.
  • 102
    Fillingim RB, Ness TJ, Glover TL, Campbell CM, Hastie BA, Price DD, Staud R. Morphine responses and experimental pain: sex differences in side effects and cardiovascular responses but not analgesia. J. Pain 2005; 6: 116–24.
  • 103
    Sprenger T, Valet M, Boecker H, Henriksen G, Spilker ME, Willoch F, Wagner KJ, Wester HJ, Tolle TR. Opioidergic activation in the medial pain system after heat pain. Pain 2006; 122: 63–7.
  • 104
    De Schepper HU, Cremonini F, Park MI, Camilleri M. Opioids and the gut: pharmacology and current clinical experience. Neurogastroenterol Motil 2004; 16: 383–394.
  • 105
    Arendt-Nielsen L, Pedersen P, Poulsen L, Andersen OK, Bjerring P, Coste I, Insuasty J, Sindrup SH, Drewes AM. A 5-HT antagonist (UP 26-91) versus codeine and placebo in a human experimental pain study. Pain Res Manage 2000; 4, 135–140.
  • 106
    Poulsen L, Brosen K, Arendt-Nielsen L, Gram LF, Elbaek K, Sindrup SH. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects. Eur J Clin Pharmacol 1996; 51: 289–95.
  • 107
    Stacher G, Bauer P, Schneider C, Winklehner S, Schmierer G. Effects of a combination of oral naproxen sodium and codeine on experimentally induced pain. Eur J Clin Pharmacol 1982; 21: 485–90.
  • 108
    Walker DJ, Zacny JP. Subjective, psychomotor, and analgesic effects of oral codeine and morphine in healthy volunteers. Psychopharmacology (Berl) 1998; 140: 191–201.
  • 109
    Guay DR, Awni WM, Halstenson CE, Findlay JW, Opsahl JA, Abraham PA, Jones EC, Matzke GR. Pharmacokinetics of codeine after single- and multiple-oral-dose administration to normal volunteers. J Clin Pharmacol 1987; 27: 983–7.
  • 110
    Srinivasan V, Wielbo D, Tebbett IR. Analgesic effects of codeine-6-glucuronide after intravenous administration. Eur J Pain 1997; 1: 185–90.
  • 111
    Enggaard TP, Poulsen L, Arendt-Nielsen L, Brosen K, Ossig J, Sindrup SH. The analgesic effect of tramadol after intravenous injection in healthy volunteers in relation to CYP2D6. Anesth Analg 2006; 102: 146–50.
  • 112
    Hummel T, Hummel C, Friedel I, Pauli E, Kobal G. A comparison of the antinociceptive effects of imipramine, tramadol and anpirtoline. Br J Clin Pharmacol 1994; 37: 325–33.
  • 113
    Thurauf N, Fleischer WK, Liefhold J, Schmid O, Kobal G. Dose dependent time course of the analgesic effect of a sustained-release preparation of tramadol on experimental phasic and tonic pain. Br J Clin Pharmacol 1996; 41: 115–23.
  • 114
    Hogger P, Rohdewald P. Comparison of tilidine/naloxone, tramadol and bromfenac in experimental pain: a double-blind randomized crossover study in healthy human volunteers. Int J Clin Pharmacol Ther 1999; 37: 377–85.
  • 115
    Narhi M, Jyvasjarvi E, Virtanen A, Huopaniemi T, Ngassapa D, Hirvonen T. Role of intradental A- and C-type nerve fibres in dental pain mechanisms. Proc Finn Dent Soc 1992; 88 (Suppl. 1): 507–16.
  • 116
    Rohdewald P, Granitzki HW, Neddermann E. Comparison of the analgesic efficacy of metamizole and tramadol in experimental pain. Pharmacology 1988; 37: 209–17.
  • 117
    Loram LC, Mitchell D, Fuller A. Rofecoxib and tramadol do not attenuate delayed-onset muscle soreness or ischaemic pain in human volunteers. Can J Physiol Pharmacol 2005; 83: 1137–45.
  • 118
    Filitz J, Ihmsen H, Gunther W, Troster A, Schwilden H, Schuttler J, Koppert W. Supra-additive effects of tramadol and acetaminophen in a human pain model. Pain 2008; 136: 262–70.
  • 119
    Minami K, Uezono Y, Ueta Y. Pharmacological aspects of the effects of tramadol on G-protein coupled receptors. J Pharmacol Sci 2007; 103: 253–60.
  • 120
    Gillen C, Haurand M, Kobelt DJ, Wnendt S. Affinity, potency and efficacy of tramadol and its metabolites at the cloned human mu-opioid receptor. Naunyn Schmiedebergs Arch Pharmacol 2000; 362: 116–21.
  • 121
    Poulsen L, Arendt-Nielsen L, Brosen K, Sindrup SH. The hypoalgesic effect of tramadol in relation to CYP2D6. Clin Pharmacol Ther 1996; 60: 636–44.
  • 122
    Angst MS, Clark JD. Comment on Koltzenburg et al.: differential sensitivity of three experimental pain models in detecting the analgesic effects of transdermal fentanyl and buprenorphine. Pain 2006; 126: 165–74. Pain 2007; 128: 292–94.
  • 123
    Yarnitsky D, Sprecher E, Zaslansky R, Hemli JA. Multiple session experimental pain measurement. Pain 1996; 67: 327–33.
  • 124
    Petersen-Felix S, Arendt-Nielsen L. From pain research to pain treatment: the role of human experimental pain models. Best Pract Res Clin Anaesthesiol 2002; 16: 667–80.
  • 125
    Chizh BA, Priestley T, Rowbotham M, Schaffler K. Predicting therapeutic efficacy – Experimental pain in human subjects. Brain Res Rev 2009; 60: 243–54.
  • 126
    Campa D, Gioia A, Tomei A, Poli P, Barale R. Association of ABCB1/MDR1 and OPRM1 gene polymorphisms with morphine pain relief. Clin Pharmacol Ther 2008; 83: 559–66.
  • 127
    Garcia R, Benet M, Arnau C, Cobo E. Efficiency of the cross-over design: an empirical estimation. Stat Med 2004; 23: 3773–80.
  • 128
    Keogh E, Barlow C, Mounce C, Bond FW. Assessing the relationship between cold pressor pain responses and dimensions of the anxiety sensitivity profile in healthy men and women. Cogn Behav Ther 2006; 35: 198–206.
  • 129
    Pincus T, Burton AK, Vogel S, Field AP. A systematic review of psychological factors as predictors of chronicity/disability in prospective cohorts of low back pain. Spine 2002; 27: E109–120.
  • 130
    Arendt-Nielsen L, Nielsen J, Petersen-Felix S, Schnider TW, Zbinden AM. Effect of racemic mixture and the (S+)-isomer of ketamine on temporal and spatial summation of pain. Br J Anaesth 1996; 77: 625–31.
  • 131
    Kalso E, Poyhia R, Onnela P, Linko K, Tigerstedt I, Tammisto T. Intravenous morphine and oxycodone for pain after abdominal surgery. Acta Anaesthesiol Scand 1991; 35: 642–6.
View Full Article (HTML) Get PDF (1378K)